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The burden of respiratory syncytial virus (RSV) 
associated acute lower respiratory infections 
in children with Down syndrome: A systematic 
review and meta–analysis
Background Acute lower respiratory tract infections (ALRIs) caused by 
respiratory syncytial virus (RSV) are a leading cause of hospitalization in 
infants. Numerous risk factors have been identified in the aetiology of se-
vere RSV–associated ALRI necessitating hospitalisation, including prema-
turity and congenital heart disease. Down syndrome (DS), a common ge-
netic disorder associated with congenital and dysmorphic features, has 
recently been identified as an independent risk factor for RSV–associated 
ALRI requiring hospitalisation; however, the disease burden of RSV–asso-
ciated ALRI in this population has not yet been established. Similarly, the 
impact of DS as an independent risk factor has not yet been quantified. 
We aimed therefore to estimate the incidence of admissions in children 
with DS, and by comparing this with unaffected children, to quantify the 
risk of DS independent of other risk factors.
Methods A systematic review of the existing literature published between 
1995 and March 1, 2017 was performed to quantify the incidence of hos-
pitalisation due to RSV–associated ALRI in children with DS. Meta–analy-
ses were performed on extracted data using STATA statistical software, and 
hospitalisation rates for children with and without DS under the age of 2 
were calculated.
Findings 5 articles were ultimately deemed eligible for analyses. Analyses 
were limited to children under the age of 2 years. We calculated the hos-
pitalisation rate for children with DS in this age group to be 117.6 per 1000 
child–years (95% CI 67.4–205.2), vs a rate of 15.2 per 1000 child–years 
(95% CI 8.3–27.6) in unaffected children. This indicates DS contributes 
to a 6.8 (95% CI 5.5–8.4) fold increase in the relative risk of hospitalisa-
tion for RSV–associated ALRI.
Interpretation Though limited by a small number of articles, this review 
found sufficient evidence to conclude DS was a significant independent 
risk factor for the development of severe RSV–associated ALRI requiring 
hospitalisation. Further studies are needed to define the impact of DS in 
conjunction with other comorbidities on the risk of severe RSV infection. 
Determining benefits of immunoprophylaxis or future vaccines against 
RSV in this at–risk population is warranted.
Electronic supplementary material: 
The online version of this article contains supplementary material.
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Respiratory syncytial virus (RSV) is one of the leading causes of acute lower re-
spiratory tract infections (ALRIs) in young children (<5 years) globally [1–3].
Almost every child will have been infected with RSV by the age of 2 years, and 
40% of these will develop ALRIs. Of these, 0.5–2% of children will require hos-
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pitalisation, making RSV–associated ALRIs the leading cause of hospitalisation among infants during win-
ter [1]. Prematurity, chronic lung disease, age <6 months, and congenital heart disease (CHD) are estab-
lished risk factors for RSV infection [4–6]. Bloemers et al. highlighted Down syndrome (DS) as an 
independent risk factor for RSV infection [7].
DS is the single most common chromosomal abnormality among live born infants, characterised by con-
genital and dysmorphic features [8]. Individuals with DS are more prone to numerous health issues, and 
the condition is associated with an overall increased risk of mortality [9,10]. Notably, ALRIs are the most 
common cause of hospitalisation among children with DS [11]. However, the burden of RSV–associated 
ALRI in children with DS is unclear. Further investigation into the epidemiology of RSV infection in pae-
diatric DS populations may help optimise patient care in this vulnerable group.
We aimed to estimate the disease burden of RSV–associated ALRI in children with DS, focussing on hos-
pitalisation and severity of disease. We also aimed to quantify the effect of DS as a dependent and inde-
pendent risk factor for hospitalisation with RSV–associated ALRI.
METHODS
Search strategy and selection criteria
We conducted a systematic literature review using a combination of search terms, hand searching of on-
line journals, and scanning of reference lists of identified citations. Two authors (JP and MC) searched the 
following databases – MEDLINE, Embase, Global Health, CINAHL, LILACS, Web of Science, IndMED, 
WHOLIS, and SIGLE. Both extracted data independently.
We included primary, population–based studies published between 1995 and March 1, 2017 reporting 
hospitalisation rates of RSV–associated ALRI in populations with DS over at least one (1) RSV season. Ar-
ticles not available in English, and articles using an unclear or inconsistent case definition were excluded. 
Studies satisfying these minimum eligibility criteria were included. The full eligibility criteria are sum-
marised in Table 1.
The review was also registered on the PROSPERO database (Record #59594). Full details of the search 
strategy used may be found on the PROSPERO database, and in Online Supplementary Document.
Definitions
ALRI has been defined as equivalent to clinical pneumonia, which is characterised by acute–onset cough 
or respiratory distress with age–adjusted tachypnoea. Down syndrome was defined as equivalent to hav-
ing trisomy 21 based on medical or census records. RSV–associated ALRI was defined as ALRI in a child 
who is RSV positive (either based on laboratory confirmation or relevant ICD codes in medical records).
To increase the data available for analysis, methodology for confirming RSV infection or coding were not 
used as eligibility criteria, with the understanding that this could limit the interpretation of the results. 
We similarly did not distinguish between first or subsequent hospitalisations.
Table 1. Inclusion and exclusion criteria
Inclusion criteria Primary population–based studies reporting incidence data for RSV ALRI requiring hospitalisation
Articles with a surveillance period of at least 1 year or 1 RSV season
Articles reporting case fatality ratios of RSV infection
Articles assessing the OR or RR for children with DS for at least 1 year
Articles confirming RSV infection by laboratory diagnosis or hospital discharge records of confirmed RSV
Articles reporting estimates for children separately by immunoprophylaxis status, if included in the study
Exclusion criteria All non–primary articles, including reviews, presentations
Articles not available in English
Articles not investigating RSV infection as a primary outcome
Articles using a case definition of influenza or influenza–like illness
Articles using an unclear or inconsistent case definition
RSV – respiratory syncytial virus, ALRI – acute lower respiratory tract infection, OR – odds ratio, RR – relative risk, DS – Down syndrome
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Data extraction
Hospitalisation rates for all populations and subgroups from relevant studies were extracted onto a Mi-
crosoft Excel 2013 database. Information regarding study characteristics, diagnostic tests used, and pop-
ulation characteristics was recorded. Outcome data and risk factor effect parameters were extracted if 
present. Relative risk and hospitalisation rate data were calculated using raw input data as well as report-
ed figures in the reviewed studies.
Data analysis
We conducted meta–analyses of the data using STATA version 11.2 (StataCorp LP, College Station TX, 
USA). Primary outcomes were hospitalisation rates of RSV–associated ALRI in children with DS or with-
out DS, and the impact of DS on hospitalisation rate expressed as relative risk. Pooled estimates with cor-
responding 95% CIs were reported based on random effects model (DerSimonian–Laird method) since 
significant heterogeneity was expected across studies [12,13].
Two meta–analyses were performed: one using hospitalisation rate data, and one with relative risk data. 
Sensitivity analyses by age were planned, but were not performed due to limited data.
RESULTS
The literature search identified 111 records for screening after excluding duplicates. Of these, 50 articles 
were reviewed fully, and 5 articles were ultimately identified as meeting our strict eligibility criteria [7,14–
17]. This is shown in Figure 1.
All 5 studies used passive hospital data and 1 used both active and passive methods of data collection. 
Study populations were under the age of 2 years [7,14,15,17], except one study which included infants 
up to 36 months [16]. All studies used hospital in–patient or out–patient data, and did not distinguish 
between first or repeat hospitalisation episodes. All studies were based in high–income countries: 3 stud-
ies were from Europe and 2 were from the USA. No studies in Asia, Africa or South America met eligibil-
ity criteria. These articles are summarised in Table 2 [7,14–17].
Data analyses focused on the <2 years old age group, given the paucity of data beyond this group. The 
implications of this decision are discussed below.
Hospitalisation rate
Four of the 5 studies were included in the meta–analysis of hospitalisation rates for children under the 
age of 2 years with and without DS. The meta–analysis found the hospitalisation rate of RSV–associated 
ALRI in children under the age of 2 years with DS was 117.6 (95% CI 67.5–205.2) per 1000 children 
per year. Comparatively, the hospitalisation rate of 
RSV–associated ALRI in children under the age of 2 
years without DS was 15.2 (95% CI 8.3–27.6) per 
1000 children per year, (P < 0.01).
The meta–estimate of relative risk of DS for hospi-
talisation with RSV–associated ALRI (including data 
from all 5 studies) in this age group was 6.8 (95% CI 
5.5–8.4).
These findings are summarised in Table 3 and Fig-
ure 2.
Disease severity data
Four of the 5 studies compared disease severity in 
children with and without DS; however, this was in-
consistent. Distinct criteria were used across the 
studies, including need for respiratory support 
[16,17], need for mechanical ventilation [16,17], 
median duration of hospital stay [14,16,17], and 
mean duration of stay [15].
Burden of acute lower respiratory infections in children with Down syndrome
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Figure 1. PRISMA flow diagram.
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The wide range of severity measures precluded formal analyses of the data; however, within the group of 
hospitalised children, RSV–associated ALRI was consistently more severe in children with DS compared 
to those without DS [14–17]. This is shown in Table 2.
Comorbidities
Three of the 5 studies investigated the role of comorbid risk factors in the epidemiology of RSV–associ-
ated ALRI in children with DS. However, there were inconsistencies in the conditions assessed, and the 
parameters used.
Only two studies formally assessed the impact of comorbid risk factors; however, analyses were limited 
to comparing populations with DS and any additional risk factors to populations with DS without any 
risk factors [7,17]. The inconsistencies between the studies precluded formal meta–analyses of the data. 
Both studies found the presence of additional risk factors generally did not significantly affect the hospi-
talisation rate, clinical presentation, or management of RSV–associated ALRI in children with DS [7,17]. 
However, Zachariah et al. noted a significantly higher use of bronchodilators in populations with DS and 
at least one additional risk factor compared to populations with DS alone [17].
Importantly, all three studies found an increased hospitalisation rate for RSV–associated ALRI in popula-
tions with DS without additional risk factors [7,16,17].
DISCUSSION
To our knowledge, this is the first systematic review and meta–analysis to report global estimates for hos-
pitalisation rates attributable to RSV–associated ALRI in children with DS compared to children without 
Table 3. Summary of articles, with meta–analyses and sensitivity analyses
Author rSV–ASSociAted ALri hoSpitALiSAtion rAte Among 
pAtientS with dS, per 1000 chiLd–yeArS (95% ci)
rSV–ASSociAted ALri hoSpitALiSAtion rAte Among  
pAtientS without dS, per 1000 chiLd–yeArS (95% ci)
rr (95% ci)
Bloemers et al. [7] 98.7 (72.1–135.1) 7.3 (1.8–29.0) 13.6 (3.3–56.4)
Fjaerli et al. [14] 153.9 (76.9–307.6) 14.0 (13.1–15.0) 11.0 (5.5–22.0)
Kristensen et al. [15] 195.5 (156.6–244.1) 27.5 (27.0–28.0) 7.1 (5.7–8.9)
Stagliano et al. [16] 96.2 (77.4–119.6) 14.2 (13.9–14.5) 6.8 (5.5–8.4)
Zachariah et al. [17] 67.5 (49.9–91.1) 12.1 (11.9–12.3) 6.0 (5.4–6.7)
Meta–analysis of all articles:
Meta–analysis for all under 2 years* 117.6 (67.4–205.2) 15.2 (8.3–2.6) 6.8 (5.5–8.4)
RSV – respiratory syncytial virus, ALRI – acute lower respiratory tract infection, RR – relative risk, CI – confidence interval
*Sensitivity analysis using data from Bloemers et al. [7], Fjaerli et al. [14], Kristensen et al. [15], and Zachariah et al. [17] only.
Table 2. Summary of articles in review
AuthorS Study Setting Study period popuLAtion hoSpitALiSAtion rAte  
(per 1000 chiLd–yeArS)
or/rr of  
hoSpitALiSAtion 
(dS VS non–dS)
SeVerity meASurement
Bloemers et al. 
[7]
Amsterdam 
and Leiden, 
Netherlands
1976 – 2005 <36 mo; 395 DS; 276 
non–DS; Not receiving 
palivizumab
DS: 98.7 (72.1–135.1) 13.6 
(3.3–56.4)Non–DS: 7.3 (1.8–29.0)
Fjaerli et al. 
[14]
Akershus, 
Norway
1993 – 2000 <2 y; 7 DS; 70 other 
non–DS high–risk; 687 
non–DS; Low–risk
DS: 153.9 (76.9–307.6) 11.0 
(5.5–22.0)
Median LoS; DS: 7.5 d; 
Non–DS: 4 d; (P < 0.001)Non–DS: 14.0 (13.1–15.0)
Kristensen et al. 
[15]
Denmark 1997 – 2003 0 – 23 mo;399 DS; 
391 584 non–DS
DS: 195.5 (156.6–244.0) 7.1 (5.7–8.9) Mean LoS; DS: 1.91 d; 
Non–DS: 1.0 d; 
(P < 0.001)
Non–DS: 27.5 (27.0–28.0)
Stagliano et al. 
[16]
USA 2005 – 2011 <36 mo; 842 DS; 
632 358 non–DS
DS: 96.2 (77.4–119.6) 6.8 (5.5–8.4) Need for respiratory support; 
DS: 9.3%; Non–DS: 1.8%; 
(P < 0.001); Median LoS; DS: 
4 d; Non–DS: 2 d;(P < 0.01)
Non–DS: 14.2 (13.9–14.5)
Zachariah et al. 
[17]
Colorado, 
USA
1995 – 2006 0 – 23 mo; 630 DS; DS: 67.5 (49.9–91.1) 6.0 (5.4–6.7) Median LoS; DS: 4–5 d; 
Non–DS: 2–3 d; (P < 0.001)Non–DS: 12.1 (11.9–12.3)
DS – patients with Down syndrome, Non–DS – patients without Down syndrome, RR – relative risk, OR – odds ratio, LoS – length of stay, d – day, mo 
– month, y – year
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Figure 2. Forest plots of (a) risk ratio of Down syndrome for 
respiratory syncytial virus (RSV)–associated ALRI requiring 
hospitalisation in children under the age of 2 years; (b) 
hospitalisation rate of RSV–associated acute lower respirato-
ry tract infection (ALRI) in children under the age of 2 years 
with Down syndrome; and (c) hospitalisation rate of RSV–
associated ALRI in children under the age of 2 years without 
Down syndrome.
A
B
C
DS. This is important since RSV remains a leading cause of 
ALRIs and hospitalisation among children globally [1,2]. We 
estimated children under the age of 2 years with DS had a 
6.8 times (95% CI 5.5–8.4) increased risk of hospitalisation 
for RSV–associated ALRI compared to children in the same 
age group without DS. This suggests DS is an important risk 
factor for RSV–associated ALRI hospitalisation and compa-
rable to other risk factors like CHD (RR 1.5–2.7) [18–21] 
and bronchopulmonary dysplasia (RR 10.7) [21].
Though meta–analyses were not performed on severity mea-
sures, studies assessing infection severity consistently found 
more severe RSV–associated ALRI in hospitalized children 
with DS compared to those without DS. Generally, a higher 
proportion of children with DS required respiratory support 
and required longer hospitalisation [14–17].
Down syndrome and RSV infection
Several proposed mechanisms explain the increased suscep-
tibility of children with DS to RSV–associated ALRI. These 
children are more likely to have airway abnormalities such 
as poor upper airway tone and abnormal lung development. 
These may contribute towards a tendency to airway compro-
mise and oedema, and thus severe ALRIs [15,22,23]. Chil-
dren with DS have also been shown to have high rates of 
CHD and pulmonary hypertension, both of which are risk 
factors for severe RSV–associated ALRI [8,20]. While these 
comorbidities are independent risk factors for the develop-
ment of severe RSV–associated ALRI, the impact of these risk 
factors in conjunction with DS remains unclear.
Immunological dysfunction may also have a role: DS has 
been associated with poor thymus development and lower 
numbers of B and T cells, which may contribute to prolonged 
infections and poor microbial clearance [24–27].
Lastly, the presence of DS may be associated with a lower 
threshold for admission, given the complex care needs which 
may be present in affected infants. This is particularly true in 
the fi rst year of life, where there is generally poorer nutri-
tional intake [16,28]. However, this does not fully explain 
the increased risk suffered by children with DS, and disease 
severity likely also has a role [7].
Comorbidities and Down syndrome
Only three studies reported hospitalisation rate data in pop-
ulations with DS and other comorbidities, limiting formal 
analyses on the role of comorbid risk factors alongside DS in 
the epidemiology of RSV–associated ALRI [7,16,17].
Children with DS often have other risk factors for severe 
RSV–associated ALRI. Notably, CHD, a signifi cant risk factor for severe RSV–associated ALRI, is comor-
bid in up to 55% of children with DS [29,30]. However, the reviewed studies consistently showed chil-
dren with DS alone remained at signifi cantly greater risk of severe RSV–associated ALRI necessitating 
hospitalisation [7,16,17].
This review suggests there are limited studies exploring the impact of DS in conjunction with other risk 
factors in the epidemiology of RSV–associated ALRI. Our preliminary fi ndings suggest children with DS 
and other risk factors are at similar risk of severe RSV–associated ALRI compared to children with DS 
alone, but further research is necessary [7,16,17].
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Palivizumab prophylaxis for children with Down syndrome
Palivizumab is a monoclonal IgG–1 antibody which has been shown to reduce the incidence of RSV hos-
pitalisation, particularly in high–risk groups [31]. However, due to the high costs associated with it, li-
censing has largely been limited to high–risk populations such as infants with haemodynamically signif-
icant CHD (HSCHD) [32].
This systematic review suggests DS alone is associated with a significantly increased risk of hospitalisa-
tion due to RSV–associated ALRI. Furthermore, our results suggest that DS alone is associated with more 
severe RSV infection. While a meta–analysis could not be performed, the consistency of the findings is 
striking. However, there are other factors to consider when discussing the benefit of immunoprophylax-
is in this population.
There are currently no large randomised–control trials investigating the efficacy of immunoprophylaxis 
for the prevention of RSV–associated ALRI specifically in children with DS. Yi et al. found a lower rate of 
RSV–related hospitalisation in infants with DS who were treated with palivizumab compared to a retro-
spective group of untreated controls [33]. A recent observational study by Mikami et al. investigated the 
efficacy of palivizumab in preventing RSV–associated hospitalisations in immunocompromised popula-
tions, including children with DS. However, the study was uncontrolled, and data for children with DS 
were not explicitly available. Further studies are therefore required to determine the efficacy of palivi-
zumab in patients with DS.
Currently, guidance for palivizumab variably includes a statement on DS. Where this is explicitly men-
tioned, the guidance further varies, from not routinely recommended to reasonably recommended [33,34]. 
Many groups cite uncertainty over the burden of disease and the efficacy of palivizumab immunoprophy-
laxis in this population as challenges limiting the guidance [33–35].
Despite being at increased risk, no studies investigating RSV vaccination or new immunoprophylactic 
agents to our knowledge have included children with DS in their study populations. Similarly, further 
information on the topic will be similarly needed to guide RSV prevention in children with DS. Notably, 
studies on safety and cost–effectiveness in this at–risk population would be helpful in establishing guid-
ance on this issue.
Study limitations
The main limitation in this study was the small number of articles eligible for analysis. This reflects the 
paucity of research in this area, and demonstrates the need for further investigation into the epidemiol-
ogy of RSV–associated ALRIs in populations with DS. Notably, several studies pooled populations with 
and without immunoprophylaxis, and were therefore excluded from the meta–analyses.
Similarly, data were limited regarding the role of comorbidities and other confounding factors such as 
CHD and immunodeficiency. Only three studies assessed the role of DS in addition to other risk factors. 
While all three studies found DS to be an independent risk factor for RSV–associated hospitalization, the 
role of DS in addition to other risk factors in the epidemiology of RSV–associated ALRI is likely complex 
and currently not clearly understood [7,15].
In particular, the excess risk carried by DS in conjunction with major risk factors remains unknown, and 
clarification in this area would help define the vulnerability of this at–risk population.
Inconsistencies between the studies reviewed also limited the internal validity of this study. Due to lim-
ited data, analyses were restricted to children under the age of 2 years. While RSV–associated ALRI pri-
marily affects younger infants (<2 years), severe infection has also been reported in older children (<5 
years) [2,16]. This may be especially true for children with DS: this review found children with DS were 
older at admission than control populations, though this was statistically insignificant [14,16,17]. How-
ever, at least one study has shown children with DS to be significantly older than unaffected children at 
time of hospitalisation [36].
Similarly, the reporting of comorbidities and disease severity, where available, was variable. Notably, stud-
ies assessing the impact of risk factors did so by the general presence or absence of risk factors, limiting 
comparisons.
The precise definition of RSV–associated ALRI varied between studies, though they were broadly similar. 
Differences arose primarily in case ascertainment, with some studies relying on laboratory–confirmed RSV 
status [7,14] and others using hospital discharge coding [15-17]. Due to paucity of studies, we did not 
December 2017  •  Vol. 7 No. 2 •  020413 6 www.jogh.org •  doi: 10.7189/jogh.07.020413
Chan et al.
V
IE
W
PO
IN
TS
PA
PE
RS
analyse data by method of case ascertainment. Notably, this review is thus subject to the limitations of the 
studies included, particularly regarding the accuracy of ICD coding.
Reporting overall hospitalisation rates may over–represent more vulnerable individuals, resulting in inac-
curate data. This effect may be exaggerated when considering some guidelines advocate admitting chil-
dren for social or geographic reasons [37,38]. Risk factors for repeated admission may be distinct from 
risk factors of severe infection, and these nuances may be lost when measuring hospitalisation rates alone.
A greater limitation in the application of this review is the scope of the review, and the socio–geographical 
bias of the eligible articles. Only five studies were retained for the meta–analyses, and all were based either 
in Europe or North America. Notably, no articles from low– and middle–income countries (LMICs) ful-
filled eligibility criteria, though previous reviews have highlighted the significant disease burden of RSV–
associated ALRI in such countries [2,39]. While DS may reasonably be assumed to be a risk factor every-
where, the burden of disease in these populations may vary depending on local public health programmes.
Another limitation of this review was the age of the studies included in the review. Much of the data used 
in the meta–analyses came from before 2005. As population health and the efficacy of medical interven-
tions have improved in this time, and continue to do so, it is possible the data do not reflect current trends 
in RSV–associated ALRI hospitalisation and standards of hospital care; this is especially true in high in-
come settings.
Guidelines for palivizumab immunoprophylaxis have also changed during this time, notably for children 
with HSCHD [33,40]. The treatment of HSCHD has similarly improved in recent years [41]. Theoreti-
cally, correcting HSCHD should reduce the risk of developing RSV–associated ALRI, though there are yet 
limited data to support this hypothesis. These developments could also affect the data in this review.
Future research
The meta–analysis identified a significant need for good data on the impact of RSV–associated ALRI in 
populations with DS. Notably, further research into the impact of DS on the epidemiology of RSV–asso-
ciated ALRI in combination with other risk factors would help clarify the burden of disease in this popu-
lation. Similarly, research investigating the risk carried by populations with DS over time could give in-
sight into the pathophysiology underlying this relationship. This would also help define the risk of 
children with DS to develop repeat episodes of RSV–associated ALRI.
Importantly, all the studies included in this review came from high–income countries in Europe or the 
Americas. Data from other geographic regions, particularly in LMICs, would help identify regional varia-
tions, and may help establish guidance for RSV prevention globally.
Similarly, to assess better the role of immunoprophylaxis, studies investigating the efficacy and tolerabil-
ity of palivizumab specifically in infants with DS are needed. Cost–effectiveness analyses in this popula-
tion may also be helpful, though these analyses may be limited by geographic variation in the costs and 
benefit of immunoprophylaxis. Furthermore, as palivizumab immunoprophylaxis becomes introduced 
more widely, the effects of changing policies on the epidemiology of RSV–associated ALRI in this popu-
lation should be explored.
CONCLUSION
This is the first systematic review investigating the burden of RSV–associated ALRI in children with Down 
syndrome. Our findings suggest this population is at significantly greater risk of severe RSV–associated 
ALRI than unaffected populations, and may benefit from being considered for immunoprophylaxis. Un-
fortunately, the efficacy of palivizumab in this population is still unclear, and warrants further research, 
including cost–effectiveness analysis. When vaccines or extended half–life antibodies against RSV will 
become available, their efficacy should be explored in this vulnerable population.
www.jogh.org •  doi: 10.7189/jogh.07.020413 7 December 2017  •  Vol. 7 No. 2 •  020413
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